Please login to the form below

Not currently logged in
Email:
Password:

Gilead Sciences in US investigation

Gilead Sciences is having its manufacturing and distribution practices investigated by the US Attorney's Office

Gilead Sciences has received a subpoena from the US Attorney's Office for the Northern District of California requesting documents related to the manufacture, and related quality and distribution practices of its HIV and hepatitis B drugs.

The subpoena involves the drugs Atripla (efavirenz tenofovir emtricitabine), Emtriva (emtricitabine), Hepsera (adefovir dipivoxil), Letairis (ambrisentan), Truvada (tenofovir emtricitabine), Viread (tenofovir) and its investigational fixed-dose combination of Truvada and Edurant (rilpivirine).

In a statement the company said it is cooperating with the civil and criminal investigation.

The case could take years to resolve and is likely to result in a substantial fine.

14th June 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics